In short
NS-863 is an investigational substance being studied as an oral treatment for pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. The clinical development programme includes a Phase 2 trial (NCT07441200) that is authorised and plans to enrol 105 participants. The trial measures change in pulmonary vascular resistance (PVR) and the number of adverse events over approximately 24 weeks.
Key points
- NS-863 is being studied as an oral treatment for pulmonary arterial hypertension (PAH).
- The single registered trial is a Phase 2 study with an authorised status.
- The trial plans to enrol 105 participants.
- Participants receive either 232 mg oral NS-863 or a matching placebo.
- The main efficacy measure is change in pulmonary vascular resistance (PVR).
- Safety is measured by the number of adverse events up to about 24 weeks.
What is NS-863?
NS-863 is an investigational substance. No marketing authorisation is recorded in the registry data, so it is not yet an approved medicine. The substance is being developed for use in pulmonary arterial hypertension (PAH), a rare and serious condition in which the blood vessels in the lungs become narrow, raising blood pressure inside the lungs and putting strain on the heart.
The trial record does not state the chemical class or mechanism category of NS-863. Because the registry data contain no product information or supplementary sources for this substance, the exact kind of molecule and its development history are not described here.
How does NS-863 work?
The available trial record does not explain how NS-863 works at a molecular level. No mechanism of action, molecular target, or pharmacological class is given in the source data. What is known from the registry is that the trial measures a change in pulmonary vascular resistance (PVR), which is a measure of how much resistance the blood vessels in the lungs put up against blood flow. Lower PVR generally means the vessels have widened and the heart faces less strain.
Because no supplementary sources are provided, the page cannot describe the specific biological pathway that NS-863 is intended to affect.
Which conditions is NS-863 studied for?
- Pulmonary arterial hypertension (PAH) — a condition in which the small arteries of the lungs become thickened or narrowed, leading to high blood pressure in the lungs, breathlessness, fatigue, and increased work for the heart.
How is NS-863 given?
In the registered trial, NS-863 is given by mouth (orally). The dose used in the study is 232 milligrams. The trial also includes a matching placebo, which is an inactive substance made to look like the study drug but containing no active medicine.
The registry does not state the pharmaceutical form (for example tablet or capsule) beyond the oral route, and no other formulations or routes of administration are recorded.
What do the clinical trials show?
One clinical trial of NS-863 is registered: a Phase 2 study in pulmonary arterial hypertension (PAH). The trial is currently authorised, meaning it has received the necessary approvals to begin or proceed. It is an interventional study, which means participants receive a specific treatment and are followed over time.
The trial plans to enrol 105 participants. People taking part are assigned to receive either NS-863 at a dose of 232 mg by mouth or a matching placebo. The study is designed to compare the two groups.
The trial has two kinds of main measures. The primary efficacy endpoint is the change in pulmonary vascular resistance (PVR), which is a measure of how much resistance the blood vessels in the lungs put up against blood flow. The primary safety endpoint is the number of participants who experience an adverse event (AE), which is any unwanted medical occurrence during the study, up to approximately 24 weeks.
The registry does not report results for this trial, so no findings on efficacy or safety are available yet. The trial is registered in ClinicalTrials.gov under the identifier NCT07441200.
What side effects are known?
The available registry data do not include a list of side effects for NS-863. The trial is designed to collect safety information by counting adverse events (AEs) up to about 24 weeks, but no results have been reported in the source data. Without supplementary sources, no known side effects can be described here.